Research programme: anti-CD5 monoclonal antibodies - Affimed Therapeutics
Alternative Names: AFM 16; AFM 17; anti-CD5Latest Information Update: 02 Oct 2021
At a glance
- Originator Affimed Therapeutics
- Class Monoclonal antibodies
- Mechanism of Action CD5 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Autoimmune disorders; Chronic lymphocytic leukaemia; Multiple myeloma
Most Recent Events
- 26 Jul 2005 Preclinical trials in Autoimmune disorders in Germany (Injection)
- 26 Jul 2005 Preclinical trials in Chronic lymphocytic leukaemia in Germany (Injection)
- 26 Jul 2005 Preclinical trials in Multiple myeloma in Germany (Injection)